At the news
? NEUTRALIMPACT 4/10 8-K filed Nov 13, 2026 at 16:05 ET
Curis reported Q3 2026 net loss of $8.1M ($1.94 per share), narrower than the consensus estimate of a $2.01 loss per share. The company has no revenue following the 2025 sale of Erivedge royalties, and cash runway extended into Q1 2027 via an October 2026 private placement. Clinical progress continues in the TakeAim CLL and TakeAim Lymphoma studies, with initial CLL data expected December 2026.
- Q3 2026 net loss of $8.1 million, or $1.94 per share, vs. $7.7 million ($9.86 per share) in Q3 2025
- No revenue reported for Q3 2026 due to sale of Erivedge royalties in Q4 2025
- Cash and cash equivalents $5.0 million as of September 30, 2026
- October 2026 private placement added net proceeds of approximately $7.5 million, extending cash runway into Q1 2027
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access